Reporting on the real-world utilization of reference rituximab and its biosimilars can help show prescribing habits and reveal cost-saving opportunities.
Samuel G. Johnson, PharmD, BCPS
Advertisement
Articles by Samuel G. Johnson, PharmD, BCPS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
How Often Do Health Insurers Deny Doctor-Recommended Care?
2
Acoramidis Shows Durable Benefit at 54 Months in ATTR-CM
3
Sudden Death in HFpEF Often Preceded by Clinical Decline
4
New Data Support Pimicotinib as Durable for Rare Tenosynovial Giant Cell Tumor
5